Home » AVAX FILES IND FOR TRIAL OF LUNG CANCER DRUG
AVAX FILES IND FOR TRIAL OF LUNG CANCER DRUG
AVAX Technologies has filed an investigational new drug application with the FDA for a Phase I/II clinical trial treating patients with Stage I and II non-small cell lung cancer.
The study will utilize AVAX's AC vaccine therapeutic, which will be given as a first-line treatment after surgery. The study endpoints include safety and a measure of cellular immunity -- delayed-type hypersensitivity to the patient's own lung cancer cells.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May